Balyasny Asset Management’s Novo Nordisk NVO Stock Holding History

Balyasny Asset Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.8M	Buy	593,500 +516,500	+671%	+$24.5M	0.03%	654
2025 Q4	$3.92M	Sell	77,000 -7,000	-8%	-$358K	0.01%	1519
2025 Q3	$4.66M	Sell	84,000 -94,800	-53%	-$5.55M	0.01%	1396
2025 Q2	$12.3M	Buy	178,800 +153,900	+618%	+$10.5M	0.02%	874
2025 Q1	$1.73M	Buy	24,900 +22,100	+789%	+$1.83M	﹤0.01%	1767
2024 Q4	$241K	Buy	+2,800	New	+$303K	﹤0.01%	2472
2024 Q1	–	Sell	-222,000	Closed	-$23M	–	2960
2023 Q4	$23M	Sell	222,000 -363,000	-62%	-$35.9M	0.04%	550
2023 Q3	$377M	Buy	+585,000	New	+$51.5M	0.77%	11

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Balyasny Asset Management's NVO Position: Q1 2026 in Review

Balyasny Asset Management reduced its Novo Nordisk (NVO) stake by 25% in Q1 2026, selling an estimated $5.92M and leaving 383,146 shares worth $14.1M. The position accounts for 0.02% of the portfolio, ranked #855.

Balyasny Asset Management first reported a position in NVO in Q1 2018 and has held it in 21 quarters since. The position peaked at $106M in Q2 2025. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Balyasny Asset Management held 383,146 shares of Novo Nordisk worth $14.1M as of Q1 2026.
Balyasny Asset Management sold 124,963 Novo Nordisk shares in Q1 2026, an estimated $5.92M.
Novo Nordisk made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #855 holding.
Balyasny Asset Management first reported a position in Novo Nordisk in Q1 2018 and has held it in 21 quarters since.
Balyasny Asset Management's Novo Nordisk position peaked at $106M in Q2 2025.
1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.